Search Results
Nov 23, 2025, 20:32 ET IEI Secures TFDA QMS Approval and ISO 13485 Certification, Reinforcing Audit-Ready Manufacturing for MedTech Design Transfers
ISO 13485:2016 certification. As one of Taiwan's manufacturers holding both domestic and international medical QMS credentials, IEI enables OEM/ODM/CDMO clients to accelerate regulatory readiness and scale production across Asia, the United States, and Europe.
More news about: IEI Integration Corp.
Nov 21, 2025, 08:00 ET BioDlink and Lepu Biopharma Celebrate Successful Launch of the World's First EGFR-Targeting ADC Drug, Marking a Major Milestone in Mutual Collaboration in Biologics CMC
leading biologics CDMO, together with Lepu Biopharma (2157.HK), announced the successful market launch of MEIYOUHENG®(Becotatug Vedotin injection) , the world's first EGFR-targeting antibody-drug conjugate (ADC). The launch also represents the first ADC fully manufactured by a CDMO to reach the
More news about: BioDlink Biopharm Co., Ltd.
Nov 21, 2025, 03:01 ET HRV Pharma and MetroChem Forge Strategic CDMO Alliance to Fast-Track High-Value NCE-1 API Development
India's first integrated Virtual API and Pharmtech company, today announced a unique, comprehensive, multi-year Contract Development & Manufacturing (CDMO) partnership with MetroChem API Pvt. Ltd., one of India's leading API development and manufacturing companies. This unique & first-of-its-kind partnership
More news about: HRV Pharma
Nov 20, 2025, 16:46 ET TetraScience und Bayer erweitern ihre Partnerschaft zur Förderung des wissenschaftlichen Datenmanagements
Bayer nutzt die Scientific Data Foundry, um wissenschaftliche Daten von Laborinstrumenten sowie externen CRO- und CDMO-Partnern in einem einheitlichen, KI-nativen Format zu zentralisieren und zu harmonisieren. Diese Implementierung beseitigt kritische Datensilos, indem
More news about: TetraScience
Nov 20, 2025, 16:45 ET TetraScience et Bayer étendent leur partenariat pour accélérer la gestion des données scientifiques
centraliser et harmoniser les données scientifiques provenant des instruments de laboratoire et des partenaires CRO (Contract Research Organization) et CDMO (Contract Development and Manufacturing Organization) externes dans un format unifié et adapté à l'IA. Cette mise en œuvre répond aux problèmes majeurs
More news about: TetraScience
Nov 20, 2025, 08:00 ET Antheia and TAPI Partner to Advance Global Commercialization Strategy for Critical Pharmaceutical Ingredients
(APIs), building blocks and key starting materials (KSM's) providing one of the industry's most comprehensive API portfolios. TAPI also offers customized CDMO services, utilizing their extensive expertise in a wide range of technologies to meet the diverse needs of partners, ensuring flexibility and excellence
More news about: Antheia
Nov 20, 2025, 06:00 ET TetraScience and Bayer Expand Partnership to Advance Scientific Data Management
Bayer uses the Scientific Data Foundry to centralize and harmonize scientific data from laboratory instruments and external CRO and CDMO partners into a unified, AI-native format. This implementation addresses critical data silos by providing seamless integration with existing workflows
More news about: TetraScience
Nov 19, 2025, 23:43 ET L'usine de bioconjugués de Piramal Pharma Solutions à Grangemouth, au Royaume-Uni, reçoit des certificats de BPF de la MHRA mis à jour
20 novembre 2025 /PRNewswire/ -- Piramal Pharma Solutions, une organisation mondiale de développement et de fabrication sous contrat (CDMO) de premier plan, qui fait partie de Piramal Pharma Ltd. (NSE : PPLPHARMA) (BSE : 543635), a le plaisir d'annoncer que son site de Grangemouth,
More news about: Piramal Pharma Solutions
Nov 19, 2025, 15:50 ET La planta de bioconjugados de Piramal Pharma Solutions en Grangemouth recibe certificados GMP de la MHRA
19 de noviembre de 2025 /PRNewswire/ -- Piramal Pharma Solutions, una organización líder mundial en desarrollo y fabricación por contrato (CDMO), perteneciente a Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), se complace en anunciar que sus instalaciones en Grangemouth, Reino Unido, han
More news about: Piramal Pharma Solutions
Nov 19, 2025, 15:47 ET Die Biokonjugat-Anlage von Piramal Pharma Solutions in Grangemouth, Großbritannien, erhält aktualisierte MHRA-GMP-Zertifikate
19. November 2025 /PRNewswire/ -- Piramal Pharma Solutions, ein weltweit führendes Auftragsentwicklungs- und Produktionsunternehmen (CDMO) und Teil von Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), freut sich bekannt zu geben, dass sein Werk in Grangemouth, Großbritannien,
More news about: Piramal Pharma Solutions
Nov 19, 2025, 15:44 ET Lo stabilimento di bioconiugati di Piramal Pharma Solutions a Grangemouth, nel Regno Unito, riceve i certificati GMP MHRA aggiornati
19 novembre 2025 /PRNewswire/ -- Piramal Pharma Solutions, organizzazione leader mondiale nello sviluppo e nella produzione su contratto (CDMO) e parte di Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), è lieta di annunciare che il suo stabilimento di Grangemouth, nel Regno Unito,
More news about: Piramal Pharma Solutions
Nov 19, 2025, 11:52 ET New DMI Solutions Brand Leverages Scale, Technical Expertise to Fuel Innovation and Deepen Customer Partnerships
a national footprint, provides redundant production capabilities, creates an agile supply chain, and reinforces TruArc's goal of building a premier CDMO platform focused on skincare, body care, color cosmetics and haircare. "Each of our manufacturing sites will continue operating
More news about: DMI Solutions
Nov 19, 2025, 10:07 ET Cellipont Bioservices and Ronawk Partner to Advance Scalable Expansion of High-Quality Mesenchymal Stem Cells and Biologics
Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), today announced a strategic collaboration with
More news about: Cellipont Bioservices
Nov 19, 2025, 02:48 ET Piramal Pharma Solutions' Bioconjugates Facility in Grangemouth, UK Receives Updated MHRA GMP Certificates
Nov. 19, 2025 /PRNewswire/ -- Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), is pleased to announce that its Grangemouth, UK facility has received updated
More news about: Piramal Pharma Solutions
Nov 19, 2025, 02:41 ET Piramal Pharma Solutions' Bioconjugates Facility in Grangemouth, UK Receives Updated MHRA GMP Certificates
Nov. 19, 2025 /PRNewswire/ -- Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), is pleased to announce that its Grangemouth,
More news about: Piramal Pharma Solutions
Nov 17, 2025, 09:06 ET Shilpa Pharma Lifesciences 憑藉卓越可持續發展實踐 榮獲 EcoVadis 金獎
Bhutada 先生在談及這一里程碑時強調：「可持續發展與創新是 Shilpa CDMO 增長策略不可或缺的元素，旨在與全球創新公司合作推展其新化學實體計劃。EcoVadis 金獎足證我們在負責任生產、道德管治及包容性增長方面的不懈努力，這一切均為患者和合作夥伴創造了持久的價值。我們期待與更多全球創新公司合作。」 這項成就進一步鞏固 Shilpa 在全球客戶、投資者和合作夥伴心目中的信譽，強化其作為值得信賴的全球 CDMO 合作夥伴、並以可持續發展為營運核心的定位。
More news about: Shilpa Medicare Limited
Nov 14, 2025, 06:00 ET Inhibrx Reports Third Quarter 2025 Financial Results
for the third quarter of 2024. The decrease was primarily related to a decrease in process development and manufacturing activities performed by our CDMO partners during the prior year in connection with the Company's clinical trial for ozekibart (INBRX-109). In addition, personnel-related expenses decreased
More news about: Inhibrx Biosciences, Inc.
Nov 14, 2025, 05:08 ET EirGenix unterzeichnete die kommerzielle Lizenzvereinbarung für sein zweites HER2-Biosimilar EG1206A
Trends beschleunigt EirGenix die Entwicklung von vier auf HER2 gerichteten Antikörperprogrammen und erweitert seine eigene Produktpipeline sowie die CDMO-Dienstleistungen für zusätzliche Biosimilar-Projekte. Da die weltweite Nachfrage nach Forschung, Entwicklung und Herstellung von Biosimilars weiter
More news about: EirGenix, Inc.
Nov 12, 2025, 20:06 ET EirGenix ha firmado el acuerdo de licencia comercial para su segundo biosimilar de HER2, EG1206A
EirGenix está acelerando el desarrollo de cuatro programas de anticuerpos dirigidos a HER2, ampliando su cartera de productos propios y sus servicios de CDMO para proyectos biosimilares adicionales. A medida que crece la demanda global de I+D y fabricación de biosimilares, la experiencia técnica, la capacidad
More news about: EirGenix, Inc.
Nov 12, 2025, 20:05 ET EirGenix a signé un accord de licence commerciale pour son deuxième actif biosimilaire HER2, l'EG1206A
EirGenix accélère le développement de quatre programmes d'anticorps ciblant HER2, élargissant son portefeuille de produits interne ainsi que ses services CDMO pour des projets de biosimilaires supplémentaires. Alors que la demande mondiale en matière de R&D et de fabrication de biosimilaires ne cesse de
More news about: EirGenix, Inc.
Nov 12, 2025, 19:32 ET AtomVie Global Radiopharma liefert die erste Patientendosis von 225Ac-SSO110 für die Phase-1/2-Studie SANTANA-225 von Ariceum Therapeutics bei kleinzelligem Lungenkarzinom im fortgeschrittenen Stadium und Merkelzellkarzinom
HAMILTON, ONTARIO, 13. November 2025 /PRNewswire/ -- AtomVie Global Radiopharma (AtomVie), ein führendes CDMO für Radiopharmazeutika, gab bekannt, dass es erfolgreich die erste Dosis 225Ac-SSO110 von Ariceum Therapeutics (Ariceum) geliefert hat, einem potenziell
More news about: AtomVie Global Radiopharma Inc.
Nov 12, 2025, 16:01 ET AtomVie Global Radiopharma suministra la primera dosis para pacientes de 225Ac-SSO110
HAMILTON, ON, 12 de noviembre de 2025 /PRNewswire/ -- AtomVie Global Radiopharma (AtomVie), una CDMO radiofarmacéutica líder, anunció que ha suministrado con éxito la primera dosis de 225Ac-SSO110 de Ariceum Therapeutics (Ariceum), un antagonista marcado
More news about: AtomVie Global Radiopharma Inc.
Nov 12, 2025, 09:00 ET Kytopen and Excellos Explore New Pathways to Non-Viral Cell Therapy Manufacturing
Nov. 12, 2025 /PRNewswire/ -- Kytopen Corp., a leader in continuous flow cellular engineering, and Excellos, Inc., a cell therapy CDMO and member of Blood Centers of America (BCA), today announced that the two companies are exploring a collaboration to advance non-viral cell therapy
More news about: Kytopen
Nov 12, 2025, 09:00 ET AtomVie Global Radiopharma Supplies the First Patient Dose of 225Ac-SSO110 for Ariceum Therapeutics' Phase 1/2 SANTANA-225 Clinical Trial in Extensive-Stage Small Cell Lung Cancer and Merkel Cell Carcinoma
HAMILTON, ON, Nov. 12, 2025 /PRNewswire/ -- AtomVie Global Radiopharma (AtomVie), a leading radiopharmaceutical CDMO, announced that it has successfully supplied the first dose of Ariceum Therapeutics' (Ariceum) 225Ac-SSO110, a potentially first- and best-in-class Actinium-225-labelled
More news about: AtomVie Global Radiopharma Inc.
Nov 12, 2025, 09:00 ET AtomVie Global Radiopharma Supplies the First Patient Dose of 225Ac-SSO110 for Ariceum Therapeutics' Phase 1/2 SANTANA-225 Clinical Trial in Extensive-Stage Small Cell Lung Cancer and Merkel Cell Carcinoma
HAMILTON, ON, Nov. 12, 2025 /PRNewswire/ - AtomVie Global Radiopharma (AtomVie), a leading radiopharmaceutical CDMO, announced that it has successfully supplied the first dose of Ariceum Therapeutics' (Ariceum) 225Ac-SSO110, a potentially first- and best-in-class Actinium-225-labelled
More news about: AtomVie Global Radiopharma Inc.